These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease. Lee A; Prideaux B; Lee MH; Zimmerman M; Dolgov E; Perlin DS; Zhao Y Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30988140 [TBL] [Abstract][Full Text] [Related]
3. Successful treatment of Aspergillus fumigatus sternal osteomyelitis with isavuconazole in a heart transplant recipient. Assaf A; Faure E; Sermet K; Loridant S; Leroy J; Goeminne C; Dozier A; Chopin MC; Panaget S; Faure K; Vuotto F Transpl Infect Dis; 2020 Oct; 22(5):e13313. PubMed ID: 32386273 [TBL] [Abstract][Full Text] [Related]
4. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791 [TBL] [Abstract][Full Text] [Related]
5. Influence of Sustained Low-Efficiency Dialysis Treatment on Isavuconazole Plasma Levels in Critically Ill Patients. Lahmer T; Batres Baires G; Heilmaier M; Schmid RM; Sörgel F; Kinzig M; Huber W; Mayr U; Rasch S Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427296 [TBL] [Abstract][Full Text] [Related]
8. Isavuconazole: Case Report and Pharmacokinetic Considerations. Marchesi F; Girmenia C; Goffredo BM; Salvatorelli E; Romano A; Mengarelli A; Minotti G; Menna P Chemotherapy; 2018; 63(5):253-256. PubMed ID: 30458443 [TBL] [Abstract][Full Text] [Related]
9. European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group. Serris A; Rautemaa-Richardson R; Laranjinha JD; Candoni A; Garcia-Vidal C; Alastruey-Izquierdo A; Hammarström H; Seidel D; Styczynski J; Sabino R; Lamoth F; Prattes J; Warris A; Porcher R; Lanternier F; Clin Infect Dis; 2024 Oct; 79(4):936-943. PubMed ID: 39076104 [TBL] [Abstract][Full Text] [Related]
10. Broad-spectrum azoles and flucloxacillin: a dangerous match. Vangheluwe T; Van Hoecke F; Dumoulin A; Vogelaers D Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):153-154. PubMed ID: 34494173 [TBL] [Abstract][Full Text] [Related]
11. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report. Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363 [TBL] [Abstract][Full Text] [Related]
13. Intravenous isavuconazole can be administered 5 days-a-week. A possibility suggested by a real-life observation. Castagnola E; Mesini A; Saffioti C; Barco S; Bandettini R; Dallorso S; Carrega G; Miano M; Palmisani E; Dufour C J Chemother; 2020 Jul; 32(4):217-218. PubMed ID: 32364049 [TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation. Oarbeascoa G; Dorado N; Bailén R; Serrano D; Balsalobre P; Pradillo V; Guinea J; Padilla B; Sancho M; Machado M; Buño I; Anguita J; Diez-Martin JL; Kwon M Chemotherapy; 2019; 64(2):57-61. PubMed ID: 31484176 [TBL] [Abstract][Full Text] [Related]
15. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds. Pfaller MA; Rhomberg PR; Castanheira M Diagn Microbiol Infect Dis; 2018 Sep; 92(1):43-45. PubMed ID: 29735424 [TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetic challenge of treating invasive aspergillosis complicating severe influenzae assisted by extracorporeal membrane oxygenation. Winiszewski H; Rougny AC; Lagoutte-Renosi J; Millon L; Capellier G; Navellou JC; Piton G; Clairet AL Crit Care; 2018 Dec; 22(1):355. PubMed ID: 30577863 [No Abstract] [Full Text] [Related]
17. Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi. Desai A; Kovanda L; Kowalski D; Lu Q; Townsend R; Bonate PL Antimicrob Agents Chemother; 2016 Sep; 60(9):5483-91. PubMed ID: 27381396 [TBL] [Abstract][Full Text] [Related]
18. [Invasive aspergillosis in solid organ transplantation]. Silva JT; Torre-Cisneros J; Aguado JM Rev Iberoam Micol; 2018; 35(4):206-209. PubMed ID: 30467000 [TBL] [Abstract][Full Text] [Related]
19. Use of triazoles for the treatment of invasive aspergillosis: A three-year cohort analysis. Cheng MP; Orejas JL; Arbona-Haddad E; Bold TD; Solomon IH; Chen K; Pandit A; Kusztos AE; Cummins KC; Liakos A; Marty FM; Koo S; Hammond SP Mycoses; 2020 Jan; 63(1):58-64. PubMed ID: 31587405 [TBL] [Abstract][Full Text] [Related]
20. [Current therapeutic options in invasive mycosis and potential therapeutic role of isavuconazole]. Garcia-Vidal C Rev Iberoam Micol; 2018; 35(4):192-197. PubMed ID: 30455108 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]